DUALITYBIO-B (09606.HK): nine directors and senior management commit to six-month voluntary lock-up

NewTimeSpace News: According to the HKEX on October 29, Duality Biotherapeutics, Inc. ("Duality Bio-B", 09606.HK) announced that its directors and senior management, based on confidence in the company's long-term value and future prospects, have voluntarily undertaken not to initiate or direct any sale or other disposal of shares directly or indirectly beneficially owned by them, including shares obtained through the exercise of share options during the lock-up period.

According to the announcement, the voluntary lock-up lasts six months from October 29, 2026 to April 28, 2027 (both days inclusive), covering nine directors and senior management members, including chairman, executive director and CEO Dr. Zhu Zhongyuan, executive director and CFO Zhang Shaoren, executive director, senior vice president and head of drug discovery Dr. Hua Haiqing, chief scientific officer Dr. Qiu Yang and global chief medical officer Dr. Mou Hua.

The company said the lock-up was made voluntarily based on confidence in its long-term value and prospects, and cautioned shareholders and potential investors to exercise caution when dealing in its securities.